Womenra: Restore Female Sexual Desire with Flibanserin
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $5.04 | $50.44 (0%) | 🛒 Add to cart |
| 20 | $3.03 | $100.89 $60.53 (40%) | 🛒 Add to cart |
| 30 | $2.35 | $151.33 $70.62 (53%) | 🛒 Add to cart |
| 60 | $1.51 | $302.67 $90.80 (70%) | 🛒 Add to cart |
| 90 | $1.23 | $454.00 $110.98 (76%) | 🛒 Add to cart |
| 120 | $1.18 | $605.34 $141.25 (77%) | 🛒 Add to cart |
| 180 | $1.01 | $908.01 $181.60 (80%) | 🛒 Add to cart |
| 270 | $0.90 | $1362.01 $242.14 (82%) | 🛒 Add to cart |
| 360 | $0.84
Best per pill | $1816.02 $302.67 (83%) | 🛒 Add to cart |
Womenra is a prescription medication specifically developed to address acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It contains flibanserin, a multifunctional serotonin agonist and antagonist that works by rebalancing neurotransmitters in the brain to help restore sexual interest and reduce associated distress. This non-hormonal treatment represents a significant advancement in women’s sexual health pharmacotherapy, offering a targeted approach to a complex neurobiological condition. Clinical studies have demonstrated its efficacy in increasing satisfying sexual events and reviving desire with a well-characterized safety profile.
Features
- Contains 100 mg of flibanserin per tablet
- Non-hormonal mechanism of action
- Central nervous system-active serotonin 1A receptor agonist
- Serotonin 2A receptor antagonist
- Once-daily bedtime administration
- FDA-approved for premenopausal women with HSDD
Benefits
- Increases the number of satisfying sexual events
- Enhances sexual desire and reduces associated distress
- Provides a non-hormonal treatment option
- Improves overall sexual satisfaction
- Helps restore natural sexual motivation
- Addresses the neurochemical basis of low desire
Common use
Womenra is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). HSDD is characterized by a persistent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by another medical or psychiatric condition, relationship problems, or the effects of a medication or drug substance. The condition must be acquired (developing in a patient who previously had no problems with sexual desire) and generalized (not situational or partner-specific).
Dosage and direction
The recommended dosage is 100 mg taken orally once daily at bedtime. Administration at bedtime is recommended to minimize the risk of adverse reactions such as dizziness, somnolence, and hypotension. Womenra should be taken consistently rather than on an as-needed basis, as it requires chronic dosing to achieve therapeutic effect. The tablet should be swallowed whole and may be taken with or without food, though consistent timing is advised. Dose adjustment is not recommended for patients with mild hepatic impairment, but Womenra is not recommended in patients with moderate or severe hepatic impairment.
Precautions
Patients should be advised about the potential for hypotension, syncope, and central nervous system depression. Alcohol use is contraindicated during treatment due to increased risk of severe hypotension and syncope. Womenra may cause drowsiness; patients should exercise caution when engaging in activities requiring complete mental alertness, such as driving or operating machinery, until they know how the medication affects them. Blood pressure should be monitored in patients taking concomitant medications that can lower blood pressure. Use with moderate or strong CYP3A4 inhibitors is contraindicated.
Contraindications
Womenra is contraindicated in patients with hepatic impairment; in patients taking strong or moderate CYP3A4 inhibitors; with concomitant use of alcohol; and in patients taking other central nervous system depressants. It should not be used in postmenopausal women or men. Womenra is also contraindicated in patients with a known hypersensitivity to flibanserin or any components of the formulation.
Possible side effects
The most common adverse reactions (≥2%) include dizziness, somnolence, nausea, fatigue, insomnia, dry mouth, and anxiety. Less common but serious side effects may include syncope, hypotension, and accidental injury. In clinical trials, syncope was reported in 0.4% of patients at the 100 mg dose. The incidence of dizziness and somnolence increases with concomitant alcohol use. Patients should report any persistent or severe side effects to their healthcare provider.
Drug interaction
Womenra is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19. Concomitant use with strong CYP3A4 inhibitors increases flibanserin exposure and is contraindicated. Moderate CYP3A4 inhibitors also significantly increase exposure and are contraindicated. Concomitant use with alcohol increases the risk of severe hypotension and syncope. Womenra may potentiate the effects of CNS depressants including benzodiazepines, opioids, and sedating antihistamines. Use with other medications that affect blood pressure may increase the risk of hypotension.
Missed dose
If a dose is missed, it should be skipped and the regular dosing schedule resumed the following night. Patients should not take two doses to make up for a missed dose. Consistent daily dosing is important for maintaining therapeutic effect, but occasional missed doses are not expected to significantly impact overall treatment efficacy.
Overdose
In case of overdose, supportive measures should be instituted with particular attention to monitoring for signs and symptoms of hypotension and syncope. There is no specific antidote for flibanserin overdose. Hemodialysis is not expected to be effective in removing flibanserin due to its high protein binding. Medical toxicology consultation is recommended for management of significant overdose.
Storage
Store at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container to protect from moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Womenra is available by prescription only and should be used under the supervision of a qualified healthcare provider. Patients should discuss their complete medical history, including all medications and supplements, with their healthcare provider before starting treatment. Individual results may vary, and not all patients will experience the same benefits.
Reviews
Clinical trial data demonstrate that Womenra significantly increases the number of satisfying sexual events and improves sexual desire compared to placebo. In phase III clinical trials, approximately 48-51% of women treated with flibanserin 100 mg reported meaningful improvement in sexual desire, compared to 31-34% of placebo-treated patients. Patients reported decreased distress associated with low sexual desire and improved sexual function scores. The most common reasons for discontinuation were dizziness, somnolence, and nausea. Real-world evidence continues to support the efficacy and safety profile observed in clinical trials.